NanoBioSensing. A Powerful New Platform For Real-Time, Continuous, Label-Free Biomarker Monitoring (Sensors USA 2018)

Dr Spencer Farr, CEO & Co-Founder
Vista Therapeutics
United States
 

Downloads

USA 2018 (pdf) Presentation - IDTechEx*
USA 2018 (audio) Presentation - IDTechEx*

If you already have access, please [Login]
Access can be purchased via IDTechEx Credits

Presentation Summary

Vista's nanoscale field effect transistors open a whole new vista into label-free, real-time continuous biomarker monitoring, PCR, antibody selection, cell motility, membrane potential, enzyme activity, kinetic and thermodynamic analysis all in a single platform.

Speaker Biography (Spencer Farr)

Dr. Spencer Farr is a biochemist trained in Bruce Ames lab at UC Berkeley, an NIH Postoctoral Fellow, A Fulbright Scholar at the Institut Jacques Monod in Paris a Faculty member in the Harvard School of Public Health and an Adjunct Professor at MIT. He Co-Founded Vista with Professor Charles Lieber, a Distinguished Professor of Chemistry at Harvard and recognized world leader in nanotechnology. Vista is Dr. Farr's third company and he believes that Vista's NanoBioSensor technology will transform biomarker analysis. He will present several examples of the NanoBioSensor in action.

Company Profile (Vista Therapeutics)

Vista Therapeutics logo
Vista Therapeutics Inc. was founded to apply advanced nanoscale electronics to address the need for versatile bioassays that can provide results on a continuous, real-time and label-free basis. Vista is a small company located in Santa Fe New Mexico where it has leveraged of the enormous capabilities of Los Alamos and Sandia National labs as well as the Center of Integrated NanoTechnology (CINT). Vista also enjoys close ties with the Harvard and U-Penn nanotechnology institutes. Vista is just now launching its highly versatile NanoBioSensor Platform System.
View Vista Therapeutics Timeline